Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 8/20 | 0.59 |
| ▸ | CACNA1I | Q9P0X4 | 4/20 | 0.59 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.59 |
| ▸ | CNR2 | P34972 | 2/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1057370 | 0.85 | CACNA1I (0.75) | CACNA1HCACNA1ICACNA1GCNR2KCNH2 | |
| SCHEMBL1065091 | 0.84 | CACNA1I (0.58) | CACNA1HCACNA1ICACNA1GCNR2KCNH2 | |
| SCHEMBL1065370 | 0.82 | CACNA1I (0.56) | CACNA1HCACNA1ICACNA1GCNR2KCNH2 | |
| SCHEMBL1063757 | 0.82 | CACNA1I (0.64) | CACNA1HCACNA1ICACNA1GCNR2KCNH2 | |
| SCHEMBL11899956 | 0.80 | CACNA1H (0.51) | CACNA1HCACNA1ICACNA1GCNR2KCNH2 | |
| SCHEMBL6903541 | 0.80 | CACNA1H (0.51) | CACNA1HCACNA1ICACNA1GCNR2KCNH2 | |
| SCHEMBL11899952 | 0.80 | CACNA1H (0.51) | CACNA1HCACNA1ICACNA1GCNR2KCNH2 | |
| SCHEMBL1060457 | 0.79 | CACNA1I (0.82) | CACNA1HCACNA1ICACNA1GCNR2KCNH2 | |
| SCHEMBL11901391 | 0.79 | CACNA1H (0.55) | CACNA1HCACNA1ICACNA1GCNR2KCNH2 | |
| SCHEMBL11901400 | 0.79 | CACNA1H (0.55) | CACNA1HCACNA1ICACNA1GCNR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010493-B1 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2016-01-27 | — | — | EP | claimed |
| US-20110112064-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-05-12 | — | — | US | claimed |
| US-20090275550-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2009-11-05 | — | — | US | claimed |
| EP-2010493-B1 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2016-01-27 | — | — | EP | disclosed |
| US-8263627-B2 | Pyridyl amide T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263627-B2 | Pyridyl amide T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110112064-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112064-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-05-12 | — | — | US | disclosed |
| US-7875636-B2 | 2-(4-isopropenylphenyl)-N-[(1R)-1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl]acetamide; epilepsy, pain, neuropathic pain, schizophrenia, Parkinson's disease, depression, anxiety, sleep disorders, psychosis, schizophrenia, cardiac arrhythmia and hypertension | MERCK SHARP & DOHME CORP. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875636-B2 | 2-(4-isopropenylphenyl)-N-[(1R)-1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl]acetamide; epilepsy, pain, neuropathic pain, schizophrenia, Parkinson's disease, depression, anxiety, sleep disorders, psychosis, schizophrenia, cardiac arrhythmia and hypertension | MERCK SHARP & DOHME CORP. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875636-B2 | 2-(4-isopropenylphenyl)-N-[(1R)-1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl]acetamide; epilepsy, pain, neuropathic pain, schizophrenia, Parkinson's disease, depression, anxiety, sleep disorders, psychosis, schizophrenia, cardiac arrhythmia and hypertension | MERCK SHARP & DOHME CORP. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090275550-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2009-11-05 | — | — | US | disclosed |
| US-20090275550-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2009-11-05 | — | — | US | disclosed |
| US-20090275550-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2009-11-05 | — | — | US | disclosed |
| WO-2007120729-A2 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112064-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | CACNA1G, CACNA1H, CACNA1I | CACNA1H 2/4885CACNA1I 3/4885CACNA1G 1/4885 |
| US-20090275550-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | CACNA1G, CACNA1H, CACNA1I | CACNA1H 2/4885CACNA1I 3/4885CACNA1G 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.